Details of the Drug

General Information of Drug (ID: DMCV0BZ)

Drug Name
RhTPO
Synonyms TPIAO (TN)
Indication
Disease Entry ICD 11 Status REF
Idiopathic thrombocytopenic purpura 3B64.10 Discontinued in Phase 3 [1]
Cross-matching ID
TTD ID
D00OEG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thrombopoietin receptor (MPL) TTIHYA4 TPOR_HUMAN Agonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Idiopathic thrombocytopenic purpura
ICD Disease Classification 3B64.10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thrombopoietin receptor (MPL) DTT MPL 8.96E-01 0.07 0.28
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
2 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
6 A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.